HHS Proposes Interim Policy to Expand Peptide Access
The health agency aims to ease compounding restrictions on popular peptides following recent expert recommendations.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Should the federal government allow pharmacies to produce peptides that lack FDA approval?
The U.S. Department of Health and Human Services has submitted an interim policy to the Office of Management and Budget to allow compounding pharmacies to produce certain peptides. The move seeks to curb reliance on gray market imports by utilizing enforcement discretion.
Why it matters
The proposal addresses concerns over the safety of foreign-sourced peptides by providing a regulated domestic alternative. If approved, the policy would allow pharmacies to compound substances like BPC-157 that were previously deemed too risky by the FDA.
An external FDA panel recently recommended lifting restrictions on 6 out of 7 peptides reviewed. Industry analysts project the total peptide market could reach a valuation of $2 billion to $3 billion.
The players
Department of Health and Human Services
The federal agency is responsible for overseeing public health policies and the regulation of medical products in the United States.
Food and Drug Administration
This federal agency is charged with protecting public health by regulating the safety and efficacy of drugs and compounded medications.
Hims & Hers
This is a telehealth company that provides access to various health and wellness treatments through digital consultations and direct-to-consumer services.
Noom
This digital health platform focuses on weight management and behavioral change programs through mobile technology and personalized coaching.
The details
The policy employs enforcement discretion to permit pharmacies to compound specific peptides without fear of FDA targeting. This shift follows a July 2026 advisory panel recommendation and aligns with expansion plans already announced by major telehealth platforms like Hims & Hers and Noom.
Timeline
July 2026: An external FDA panel recommended lifting restrictions on six of seven reviewed peptides.
October 8, 2026: The Department of Health and Human Services submitted the interim access policy to the Office of Management and Budget.
Market Landscape
The policy marks a departure from the current FDA prohibited drug compounding list by introducing enforcement discretion for previously banned substances. This shift positions the agency to compete with the illicit market while providing a pathway for commercial telehealth growth.
If the policy is finalized, consumers may gain access to domestically compounded peptides through authorized telehealth providers. This could provide a safer alternative to the current unregulated gray market for those seeking these treatments.
The takeaway
This development suggests a potential regulatory shift toward providing safer domestic avenues for popular wellness treatments. Readers should wait for official guidance before pursuing any compounded peptide therapy to ensure compliance with updated FDA enforcement standards.
Further reading
For broader context on federal health regulations, visit United States Healthcare.
Live Poll
Should the federal government allow pharmacies to produce peptides that lack FDA approval?
